Purpose: The purpose of this amendment is to incorporate newly-published literature to provide a rational basis for the management of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Conclusions: Given the rapidly evolving nature of this field, this guideline should be used in conjunction with recent systematic literature reviews and an understanding of individual patients' treatment goals. Shared decision-making incorporating patients' preferences and personal goals should be implemented when choosing management strategies. This guideline will be continually updated as new literature emerges.
INTRODUCTION Incidence and Epidemiology
Prostate cancer is the most commonly diagnosed solid organ malignancy in US men and remains the second leading cause of cancer-related mortality in this population. Approximately 165,000 new diagnoses of prostate cancer and nearly 30,000 deaths were estimated for the US in 2018. 1 Death from prostate cancer is typically the result of metastatic castration-resistant prostate cancer (mCRPC), and historically the median survival for men with mCRPC has been less than two years. The recent availability of novel treatments for mCRPC has given a resurgence of hope for these men as studies now demonstrate improved survival This document is being printed as submitted independent of editorial or peer review by the editors of The Journal of UrologyÒ.
with a variety of new agents, with many men now living with CRPC for five or more years. However, until recently, there were few therapeutic options for men with non-metastatic disease to slow progression to mCRPC or delay the need for cytotoxic chemotherapy. While multiple options now exist for CRPC patients, the unfortunate reality remains that mCRPC is an incurable disease. It is against this backdrop that we look to the future with cautious optimism and new hope for scientific discovery.
The treatment of men with CRPC has dramatically changed over the past decade. Prior to 2004, once patients failed primary androgen deprivation, treatments were administered solely for palliation. Landmark articles by Tannock et al. 2 and Petrylak et al. 3 demonstrated survival benefits associated with docetaxel in men with mCRPC. Since the approval of docetaxel, six additional agents that show a survival benefit have been approved by the U.S. Food and Drug Administration (FDA) on the basis of randomized clinical trials. These have included enzalutamide, abiraterone, and apalutamide, agents designed specifically to affect the androgen axis; 4e6 sipuleucel-T, which stimulates the immune system; 7 cabazitaxel, a chemotherapeutic agent; 8 and radium-223, a radionuclide therapy. 9 These agents have been tested in multiple "disease states" of CRPC to determine if or when patients might benefit from each treatment. Other treatments for men with CRPC have been shown to improve outcomes, but have yet to be approved by the FDA.
Guideline Purpose
As a direct result of the availability of multiple FDA-approved therapeutic agents for use in patients with CRPC, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. To assist in clinical decision-making, six Index Patients were developed representing the most common clinical scenarios that are encountered in clinical practice.
1. Asymptomatic non-metastatic CRPC 2. Asymptomatic or minimally-symptomatic, mCRPC without prior docetaxel chemotherapy 3. Symptomatic, mCRPC with good performance status and no prior docetaxel chemotherapy 4. Symptomatic, mCRPC with poor performance status and no prior docetaxel chemotherapy 5. Symptomatic, mCRPC with good performance status and prior docetaxel chemotherapy 6. Symptomatic, mCRPC with poor performance status and prior docetaxel chemotherapy
The newly incorporated literature from the 2018 amendment specifically relates to Index Patient 1. A summary of the statements relating to all Index Patients can be found in Figure 1 .
METHODOLOGY Process for Initial Literature Selection
Consistent with the AUA published guideline methodology framework, 10 the process started by conducting a comprehensive systematic review. The evidence report was limited to English-language, peer-reviewed literature published between January 1996 and February 2013. Controlled vocabulary supplemented with keywords was used to search for the relevant concepts of prostate cancer and castration resistance (biochemical recurrence with a rising prostate-specific antigen [PSA] and/or progression of disease by radiographic criteria despite a castrate testosterone level). An expert panel manually identified additional references to supplement the electronic search, which were required to meet the same criteria as the previously used studies.
The search strategy focused on commonly used as well as experimental therapies, including systemic chemotherapy (estramustine, mitoxantrone, docetaxel, cabazitaxel), immunotherapy (sipuleucel-T) and vaccine therapy, agents targeting the androgen signaling pathway (abiraterone, ketoconazole, corticosteroids, antiandrogens), radiotherapy and radiopharmaceuticals (strontium-89, samarium-153, radium-223), antiandrogen withdrawal, bone targeted therapies (zoledronic acid, denosumab), androgen receptor (AR) inhibitors (enzalutamide), palliative care and experimental therapy (CYP-17 inhibitor [TAK700], cMET/VEGFR inhibitor [cabozantanib] ).
The initial systematic review included 303 eligible studies that addressed the pre-identified questions of interest. A large body of evidence evaluated established chemotherapy agents, such as docetaxel, estramustine, and mitoxantrone. Randomized evidence was also available for various immunotherapies, therapies targeting the androgen signaling pathway, radiotherapy and radiopharmaceuticals, and bone-targeting therapies. The methodological quality of these trials was acceptable overall and considered to have moderate to low risk of bias. All the remaining studies were otherwise nonrandomized (observational) and considered to be at high risk of bias.
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Guideline Amendments
In April 2014, March 2015, and May 2018, the CRPC guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published guidelines in an effort to maintain currency. The amendments allowed for the incorporation of additional literature released since the initial publication of this guideline in 2013. Comprehensive searches of several databases from February 2013 to February 2014 (2014 amendment), 12 February 2014 to February 2015 (2015 amendment), 13 and February 2015
to May 2018 (2018 amendment) were conducted. The searches were limited to English language text. The search strategies were designed and conducted by an experienced librarian with input from the guideline methodologist. Controlled vocabulary supplemented with keywords was used to search for studies on therapy for CRPC. The 2018 search yielded 770 references, of which 700 were excluded after abstract and title screening. Full texts were retrieved for 70 studies. Eventually, 47 studies that provided relevant data were included for data abstraction. Of those, five contained data specific to nonmetastatic CRPC and were included in the final update report. The resulting amendment focused on the incorporation of additional information on the treatment of non-metastatic CRPC patients.
Limitations of the Literature
The systematic review and subsequent amendments identified clear gaps in the available evidence base. None of the therapies identified were curative or resulted in long term remission. Therefore, primary research on new agents is clearly needed for this important and common condition. Future trials should also use and incorporate patient reported outcomes, such as quality of life (QoL) and pain control. The current evidence base suffers from imprecision that can be overcome by multi-site randomized controlled trial collaboration or prospective (preplanned) meta-analyses.
INDEX PATIENT 1: ASYMPTOMATIC NON-METASTATIC CRPC
One of the first clinical presentations of CRPC occurs in a patient with a rising PSA despite medical or surgical castration. Non-metastatic CRPC is typically defined as a patient with a rising PSA and no radiologic evidence of metastatic prostate cancer. The Prostate Cancer Clinical Trials Working Group 2 defines PSA only failure as a rising PSA that is greater than 2ng/mL higher than the nadir; the rise has to be at least 25% over nadir, and the rise has to be confirmed by a second PSA at least 3 weeks later. In addition, the patient is required to have castrate levels of testosterone (less than 50 ng/dL) and no radiographic evidence of metastatic disease.
14 These patients represent a relatively common clinical presentation and the earliest clinical manifestation of castration resistance. Until recently, no agent had demonstrated significant benefit in large Phase 3 trials in the nonmetastatic CRPC patient population. In February 2018, apalutamide became the first FDA-approved treatment for patients with non-metastatic CRPC. Enzalutamide has also been shown to offer benefits in this patient population, with FDA approval being granted in July 2018.
Apalutamide is a nonsteroidal anti-androgen. This oral agent acts as an AR inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. It has a 7-to 10-fold greater affinity for the AR compared to bicalutamide, a firstgeneration anti-androgen. 15 In the double-blind, placebo-controlled, Phase 3 SPARTAN trial, Smith et al. randomly assigned 1,207 men in a 2:1 ratio to receive apalutamide (240 mg per day) or placebo. 6 All patients had a diagnosis of non-metastatic CRPC with a PSA doubling time 10 months and continued on androgen deprivation therapy (ADT). At the time of planned primary analysis, median metastasis-free survival (MFS) was 40.5 months in the apalutamide group compared to 16.2 months in the placebo group (HR¼0.28; 95% CI, 0.23 to 0.35; P<0.001), representing a 72% reduction in the risk of distant metastasis or death. Median overall survival (OS) was not reached in the apalutamide group versus 39.0 months in the placebo group (HR¼0.70; 95% CI, 0.47 to 1.04; p¼0.07). Note, given the time required for maturation of OS data in such trials, MFS is now a commonly used surrogate endpoint defined as time from randomization to date of first evidence of recorded distant metastases or death, whichever occurs first. Additionally, secondary endpoints including time to symptomatic progression (HR¼ 0.45; 95% CI, 0.32 to 0.63; P<0.001) and time to metastasis (HR¼0.27; 95% CI, 0.22 to 0.34, p<0.001) were significantly longer in the apalutamide arm compared to placebo. Median progressionfree survival was 40.5 months in the apalutamide group versus 14.7 months in the placebo group (HR¼0.29; 95% CI, 0.24 to 0.36; p<0.001). Overall, 10.6% of patients receiving apalutamide discontinued treatment due to adverse events compared to 7.0% of patients receiving placebo. 7 .5%), and falls (15.6% versus 9.0%). Other adverse events of interest when apalutamide was compared to placebo included fracture (11.7% versus 6.5%), dizziness (9.3% versus 6.3%), hypothyroidism (8.1% versus 2.0%), mental-impairment disorders (5.1% versus 3.0%), and seizure (0.2% versus 0%). Of note, events related to hypothyroidism were all grade 1 or 2, were generally identified early following initiation of apalutamide treatment, and were managed with medical therapy. Particular attention should be paid to monitoring thyroid stimulating hormone in individuals with known hypothyroidism given observed changes in thyroid function with apalutamide treatment.
Enzalutamide is a novel AR signaling inhibitor. It is a competitive inhibitor of androgen binding and also inhibits nuclear translocation of the AR, DNA binding and coactivator recruitment. This drug binds AR with a five-to eight-fold higher affinity than bicalutamide. 16 Enzalutamide was previously FDA approved for use in mCRPC both pre-and postchemotherapy.
PROSPER is a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of enzalutamide in nonmetastatic CRPC patients. 17 All patients had M0 CRPC with a PSA doubling time 10 months (median PSA doubling time, 3.7 months) and PSA 2ng/mL. The 1,401 patients were randomized (2:1) to enzalutamide 160 mg per day or placebo. Both arms continued ADT. During the first interim analysis of OS, 103 patients (11%) in the enzalutamide group and 62 (13%) in the placebo group had died. Median OS was not reached in either group; however, there was a 20% reduction in the relative risk of death with enzalutamide compared to placebo. As of June 2017, a total of 219 patients (23%) in the enzalutamide group had metastases or had died, as compared with 228 (49%) in the placebo group. Median MFS was approximately 22 months longer in the enzalutamide arm at 36.6 months compared to 14.7 months in the placebo group (HR¼0.29; 95% CI 0.24 to 0.35; P<0.001). Additionally, median time to PSA progression was approximately 33 months longer in patients receiving enzalutamide compared to those receiving placebo with a 93% reduction in the relative risk of PSA progression (37.2 months in the enzalutamide group compared to 3.9 months in the placebo group; HR¼ 0.07; P<0.001). Adverse events as the primary reason for treatment discontinuation occurred in 87 patients (9%) receiving enzalutamide compared to 28 patients (6%) receiving placebo. Deaths due to adverse events on trial irrespective of attribution occurred in 32 patients (3%) receiving enzalutamide and 3 patients (1%) receiving placebo. Adverse events noted to occur more frequently with enzalutamide included convulsion, hypertension, neutropenia, memory impairment disorders, and major cardiovascular events.
The STRIVE trial, which randomized (1:
Since all agents have potential side effects and only the standard therapies have demonstrated evidence of benefit, it is the panel's judgment that no treatment (i.e. observation) other than continued ADT be recommended for patients who do not desire or cannot have a standard therapy. Given the absence of data demonstrating benefit to anything other than standard therapies in this disease setting, it is the panel opinion that such patients should be offered clinical trial enrollment, when available.
Guideline Statement 3
Clinicians may offer treatment with a secondgeneration androgen synthesis inhibitor (i.e. abiraterone plus prednisone) to select patients with non-metastatic CRPC at high risk for developing metastatic disease who do not want or cannot have one of the standard therapies and are unwilling to accept observation. (Option; Evidence Level Grade C)
There may exist a subset of patients who do not want or cannot have a standard therapy and are uncomfortable with treatment with continued ADT alone. Such patients may wish to initiate additional treatment despite the lack of high quality evidence with regards to benefits and harms in this setting. For such patients, clinicians may offer abiraterone plus prednisone as an option that has shown superior survival benefits in mCRPC and metastatic high-risk castration-sensitive prostate cancer.
Abiraterone is an irreversible inhibitor of the hydroxylase and lyase activities of CYP17A, which catalyzes the conversion of C21 progesterone precursors to C19 adrenal androgens, DHEA and androstenedione. 19 While abiraterone is considered a standard therapy in other patient populations, it is not FDA-approved for non-metastatic patients. This agent was recently FDA-approved in combination with prednisone for the treatment of men with metastatic high-risk castration-sensitive prostate cancer. Prior to this, it was initially FDA-approved for patients with mCRPC who had received prior chemotherapy; the indication was then expanded for patients with mCRPC prior to chemotherapy. Though it is generally well tolerated and is associated with fewer serious adverse events compared to other available therapies, such as ketoconazole or first-generation anti-androgens, abiraterone is associated with expected increases in mineralocorticoids upstream of CYP17A, accounting for the treatment-related side effects, such as hypertension, hypokalemia, edema and fatigue that respond to low dose glucocorticoids. Use of abiraterone in combination with low-dose prednisone is required to manage these treatment-related increases in ACTH and attendant side effects. Prior to potential initiation of abiraterone therapy in this patient population, clinicians should carefully discuss the risks and benefits with patients, particularly those with significant baseline comorbidities. The evidence for this Index Patient is rated Grade C due to a lack of significant long-term data in this specific population showing survival benefits.
Guideline Statement 4
Clinicians should not offer systemic chemotherapy or immunotherapy to patients with non-metastatic CRPC outside the context of a clinical trial. (Recommendation; Evidence Level Grade C)
The past few years have seen a plethora of new treatments for men with mCRPC. Indeed, multiple agents (e.g., docetaxel, various checkpoint inhibitors) have been shown to prolong survival for men with mCRPC. Only some such agents have been studied in this patient population and shown clinical benefit. Thus, the panel strongly recommends against this practice due to a lack of outcome data in the non-metastatic disease setting.
Of the classes of agents recommended against, only denosumab has been systematically studied in this non-metastatic state. Denosumab 120 mg subcutaneously monthly, which in a placebo-controlled randomized trial, 20 was shown to modestly delay the development of radiographically detected bone metastases, but it did not impact QoL or OS. This agent showed only a modest delay in bone metastases and was specifically denied approval by the FDA for this indication. It was associated with significant side-effects, including osteonecrosis of the jaw. Thus, monthly denosumab is not indicated for non-metastatic CRPC.
The primary reason the panel recommends against the routine use of these agents in the nonmetastatic setting is concern surrounding the risk of serious adverse events without high quality evidence supporting efficacy. All of the agents not recommended have the potential for significant toxicity. While this toxicity may be greater for some classes (i.e. chemotherapy) than others, all of these agents have the potential to harm patients. Thus, the combination of no known benefit with known and potentially serious harms results in a recommendation not to use these agents.
As the 2018 amendment literature search targeted non-metastatic CRPC patients, the statements for Index Patients 2-6 as well as those discussing bone health remain unchanged from the 2015 iteration and are available at AUAnet.org.
INDEX PATIENT 2: ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC, MCRPC WITHOUT PRIOR DOCETAXEL CHEMOTHERAPY
This patient represents a common clinical presentation seen in the CRPC setting today. These patients are characterized as having a rising PSA in the setting of castrate levels of testosterone, documented metastatic disease on radiographic imaging and no prior treatment with docetaxel chemotherapy for CRPC. The key distinction between this patient and Index Patients 3 and 4 is symptom status. Specifically, this patient is defined as having no symptoms or mild symptoms attributable to his prostate cancer. However, one must then consider whether the patient requires regular opioid pain medications for symptoms thought to be attributable to documented metastases to achieve this level of pain control. In general, if patients require regular narcotic medications for pain relief, they are not included in this category.
INDEX PATIENT 3: SYMPTOMATIC, MCRPC WITH GOOD PERFORMANCE STATUS AND NO PRIOR DOCETAXEL CHEMOTHERAPY
These patients have a rising PSA in the setting of castrate levels of testosterone, documented symptomatic metastatic disease on radiographic imaging and no prior history of docetaxel chemotherapy for prostate cancer. The definition of symptomatic disease warrants additional explanation to contrast with Index Patient 2. First, the patient must have symptoms that are clearly attributable to the metastatic disease burden, not any other medical condition. Second, if having pain, the patient should require regular opiate pain medications for symptoms attributable to documented metastases in order to achieve an acceptable level of pain control. If patients require regular narcotic medications for pain relief, then they are symptomatic from their prostate cancer and should be included in this category.
INDEX PATIENT 4: SYMPTOMATIC, MCRPC WITH POOR PERFORMANCE STATUS AND NO PRIOR DOCETAXEL CHEMOTHERAPY
Clinical trials have generally excluded patients with a poor performance status (ECOG 3-4) from participation. Thus, most data regarding management of such patients is extrapolated from randomized trials of eligible patients who had a better performance status, as well as from some smaller trials and registries. Even a Phase 3 clinical trial that was presumptively designed for a population considered "unfit" for docetaxel (ALSYMPCA to evaluate radium-223) 21 still only allowed a performance status of ECOG 0-1. However, treatments with acceptable safety profiles do exist and should be considered, even in poor performance status patients. This is especially true in those patients in whom the poor performance status may be considered to be directly related to the cancer itself and thus whose status might improve with effective treatment. Treatments must be individually tailored in these patients after a careful discussion of risks and benefits with particular attention to patient QoL.
INDEX PATIENT 5: SYMPTOMATIC, MCRPC WITH GOOD PERFORMANCE STATUS AND PRIOR DOCETAXEL CHEMOTHERAPY
As patients with prostate cancer receive hormonal therapy earlier in the course of the disease (frequently for non-metastatic disease), they may actually develop castration-resistant disease (based on serologic progression) with non-metastatic or asymptomatic metastatic disease. Thus, additional agents, including docetaxel chemotherapy may be administered earlier in the course of metastatic disease. These trends have resulted in a population of mCRPC patients who have completed docetaxel and may continue to be asymptomatic or minimallysymptomatic with an excellent performance status. While such patients may be healthy enough to receive a number of subsequent therapies, a focus of therapy should also be to maintain their excellent performance status without significant toxicity from additional therapy. It is in this context that providers should choose from a number of additional therapies to offer to this patient population.
INDEX PATIENT 6: SYMPTOMATIC, MCRPC WITH POOR PERFORMANCE STATUS AND PRIOR DOCETAXEL CHEMOTHERAPY
The American Society of Clinical Oncology has posted recommendations regarding treatment for patients with advanced solid tumors; particularly in the last months of life. These recommendations advocate for an increasing emphasis on a patient's QoL and concentrates on symptom management. Treatment given in the last months of life may delay access to end of life care, increase costs and add unnecessary symptom management. Patients with poor performance status (i.e. ECOG 3 or 4) should not be offered further treatment.
BONE HEALTH: NOT SPECIFIC TO ANY ONE INDEX PATIENT
Several factors conspire to place the average patient with metastatic prostate cancer at a higher risk of bone complications. First, the median age of onset of the disease is in the late 60s, meaning that the average patient with metastatic disease may be in his 70s (or beyond), clearly a population at risk of physiologic, age-related decreases in bone mineral density. Secondly, a primary therapeutic intervention in patients with recurrent disease (i.e. ADT) is associated with progressive loss of bone mineral density, not infrequently to the point of measurable osteopenia or frank osteoporosis, increasing the patient's fracture risk, even in patients with nonmetastatic disease. 22, 23 Finally, in patients with advanced disease, bones are the most common site of metastatic disease, with as many as 70% of patients at some point in their course demonstrating evidence of disease in this site.
FUTURE DIRECTIONS
Over the past 15 years there has been unparalleled scientific progress and investment in drug development for patients with CRPC. As a direct result of these studies, several lines of systemic therapies have been FDA approved for use in CRPC on grounds of pain palliation, minimizing disease adverse effects, and prolonging survival.
The impact on survival in CRPC from each of the individual agents discussed thus far continues to be modest, being measured only in months. To further impact outcomes therapy, development in this stage of disease must focus on the totality of disease biology integrating a comprehensive molecular understanding of castration resistance and investigating mechanisms of resistance to current therapies so as to better guide future treatment development. Continued investments in discovery, investigation and validation of important new candidate targets is needed.
One of the glaring deficiencies in prostate cancer drug development, by comparison to several other solid tumors, has been the lack of predictive biomarkers to help better personalize therapy. This is especially important if we are to optimize risk/ benefit, particularly given that a significant percentage of patients do not benefit or have small benefits from current FDA approved agents.
In addition to the continued investigation of new agents in the non-metastatic CRPC and mCRPC populations, it is critical that we prospectively define the optimal sequence of approved treatments in order to guide proper use taking into account efficacy and cost-effectiveness, particularly for agents that target similar pathways. Furthermore, maximizing the anti-tumor effect by investigating scientifically rational combinations should be an area of high priority. The mission of the original and amendment panels was to develop clinical guideline recommendations based on an in-depth evidence report of the peer-reviewed literature. The recommendations are based on evidence strength, or where evidence is not available, on Delphi-modification consensus statements. The purpose of each guideline is to provide physicians and non-physician providers (primary care and specialists) with a consensus of principles and treatment plans for the management of castration-resistant prostate cancer. While these guidelines do not necessarily establish the standard of care, AUA seeks to recommend and to encourage compliance by practitioners with current best practices related to the condition being treated.
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As medical knowledge expands and technology advances, AUA guidelines are subject to change. Evidence-based guidelines statements are not absolute mandates but thoroughly considered strategies for best practice under the specific conditions described in each document. For all these reasons, the guidelines do not pre-empt physician judgment in individual cases. Treating physicians must take into account variations in resources, and patient tolerances, needs, and preferences. Similarly, conformance with any clinical guideline cannot assure a successful outcome. These guidelines and best practice statements are not intended to provide legal advice.
The guideline text may include information or recommendations about certain drug or device use ('off label') that are not approved by the FDA, or about medications or substances not subject to the FDA approval process. AUA urges strict compliance with all government regulations and protocols for prescription and use of these substances. The physician is encouraged to understand and carefully follow all available prescribing information about indications, contraindications, precautions and warnings.
Although guidelines are intended to encourage best practices and to reflect available technologies with sufficient data as of the date of close of the literature review, guidelines are necessarily timelimited. Guidelines cannot include evaluation of all data on emerging technologies, pharmaceuticals or management practices, including both those that are FDA-approved, or those which may immediately come to represent accepted clinical practices. For this reason, the AUA does not regard emerging technologies or management techniques not addressed by this guideline as manifestly experimental or investigational. These emerging technologies or techniques may simply be too new to be included or fully incorporated in the panel's evidence-based evaluation at the time the guideline is developed.
